{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:48:04Z","timestamp":1780667284403,"version":"3.54.1"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Factor XI (FXI) deficiency is associated with bleeding after invasive procedures. Risks of human plasma\u2010derived FXI replacement products include transfusion transmitted infection, thrombosis and fluid overload. This study was designed to test the hypothesis that recombinant factor VIIa (rFVIIa) is an effective haemostatic agent in patients with FXI deficiency undergoing surgery. Fourteen FXI deficient patients [five severely deficient (FXI:C &lt;20\u2003U\u2003dL<jats:sup>\u22121<\/jats:sup>) and nine partially deficient (FXI:C 20\u201370\u2003U\u2003dL<jats:sup>\u22121<\/jats:sup>] received rFVIIa to prevent surgical bleeding during five major, four minor and six dental procedures. Minor surgical and dental procedures were covered with two doses of rFVIIa (90\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup> i.v.), the first pre\u2010operatively and the second 4\u2003h postoperatively. Major surgery was covered with 90\u2003\u03bcg\u2003kg<jats:sup>\u22121<\/jats:sup> i.v. two hourly for the first 24\u2003h and four hourly for the second 24\u2003h. Oral tranexamic acid was given for 7\u2003days postoperatively. Effective haemostasis was observed in all cases and no alternative haemostatic agents or blood transfusions were required. Three adverse events were recorded; an acute cerebrovascular accident in a patient with a history of cardiovascular disease, an allergic reaction and local phlebitis. In this study, rFVIIa was an effective alternative to plasma\u2010derived FXI replacement for the prevention of surgical bleeding in FXI deficient patients but rFVIIa may not be suitable for patients with pre\u2010existing risk factors for thrombosis.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01663.x","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T09:40:58Z","timestamp":1207042858000},"page":"775-781","source":"Crossref","is-referenced-by-count":43,"title":["Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency"],"prefix":"10.1111","volume":"14","author":[{"given":"N. M.","family":"O'CONNELL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F.","family":"RIDDELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"PASCOE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"PERRY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,8]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646162"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb02409.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653750"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00080.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199711000-00005"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440683.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199203040-00014"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00155.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1314.1314"},{"key":"e_1_2_8_11_2","first-page":"1157","article-title":"Clinical experiences of a FXI concentrate; possible side\u2010effects","volume":"65","author":"Gitel SN","year":"1991","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92237-3"},{"issue":"1","key":"e_1_2_8_13_2","first-page":"13","article-title":"A decade of experience with a factor XI concentrate","volume":"2","author":"Briggs NJ","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648439"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1992.32993110761.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.3035.3035"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119412"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.175"},{"issue":"1","key":"e_1_2_8_19_2","first-page":"S61","article-title":"Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high\u2010dose activated factor VII","volume":"9","author":"Hoffman M","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8455"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02870.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199008000-00009"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00590.x"},{"key":"e_1_2_8_24_2","article-title":"Recombinant activated factor VIIa as haemostatic agent in homozygous factor XI deficient patients","author":"Musso R","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200110000-00007"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8461"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200107000-00001"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-4722-4_7"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2794"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00017.x"},{"issue":"1","key":"e_1_2_8_31_2","first-page":"102","article-title":"Dosing and monitoring NovoSeven treatment","volume":"26","author":"Hedner U","year":"1996","journal-title":"Haemostasis"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00944.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00195.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01120.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01276.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00006"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00478.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00029"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00242.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04173.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200009000-00002"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01304.x"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01663.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01663.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:00:49Z","timestamp":1697187649000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01663.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01663.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01663.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}